ライフサイエンスコーパス: chronic lymphocytic leukemia

1 F3B1 mutations (myelodysplastic syndrome and chronic lymphocytic leukemia).

2 exed loss-of-function mutations recurrent in chronic lymphocytic leukemia.

3 mice, which develop disease resembling human chronic lymphocytic leukemia.

4 atment of a specific subset of patients with chronic lymphocytic leukemia.

5 gion are important in clinical management of chronic lymphocytic leukemia.

6 nd diseased tissues in colorectal cancer and chronic lymphocytic leukemia.

7 r, gastric, brain cancers, neuroblastoma and chronic lymphocytic leukemia.

8 nib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia.

9 CR was more than 30 months in a patient with chronic lymphocytic leukemia.

10 in treatment of B cell malignancies such as chronic lymphocytic leukemia.

11 oclax is a BH3 mimetic approved for treating chronic lymphocytic leukemia.

12 -15b/16-2 loss in the pathogenesis of B-cell chronic lymphocytic leukemia.

13 L), two had indolent lymphomas, and four had chronic lymphocytic leukemia.

14 a high penetrance of cutaneous melanoma and chronic lymphocytic leukemia.

15 endamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia.

16 es such as diffuse large B cell lymphoma and chronic lymphocytic leukemia.

17 k for Hodgkin lymphoma (3.53 [.48-25.9]) and chronic lymphocytic leukemia (1.45 [.45-4.66]) were incr

18 rs (range, 43-83 years), and 14 patients had chronic lymphocytic leukemia, 2 had classic Hodgkin lymp

19 ormed according to International Workshop on Chronic Lymphocytic Leukemia 2008 criteria.

20 D88(L265P) mutation is found in 2% to 10% of chronic lymphocytic leukemia, 29% of activated B-cell ty

21 with the evaluation of clinical response in chronic lymphocytic leukemia according to the 2008 Inter

22 Conclusion Relapse of chronic lymphocytic leukemia after ibrutinib is an issue

23 f a female immunocompromised individual with chronic lymphocytic leukemia and acquired hypogammaglobu

24 A man in his early 70s with a diagnosis of chronic lymphocytic leukemia and being treated with pred

25 IRI's broader utility in analogous models of chronic lymphocytic leukemia and breast adenocarcinoma a

26 rging application of these new techniques to chronic lymphocytic leukemia and examine the insights al

27 ty to better understand the heterogeneity of chronic lymphocytic leukemia and how mutations, activati

28 ecifically, we uncovered tsRNA signatures in chronic lymphocytic leukemia and lung cancer and demonst

29 Responses also occurred in chronic lymphocytic leukemia and lymphoma.

30 eCyPA also promoted the migration of chronic lymphocytic leukemia and lymphoplasmacytic lymph

31 osine kinase inhibition by ibrutinib in both chronic lymphocytic leukemia and mantle cell lymphoma (M

32 ll lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leukemia and multiple myeloma.

33 lonal hematopoiesis, acute myeloid leukemia, chronic lymphocytic leukemia, and a variety of solid tum

34 numerous tumors including multiple myeloma, chronic lymphocytic leukemia, and DLBCL.

35 cute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma.

36 mall molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported CDK6 as a di

37 ruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute

38 aling substantially changed the treatment of chronic lymphocytic leukemia as the first targeted agent

39 We further determined that the chronic lymphocytic leukemia-associated H266L substituti

40 f 40% knockout mice, a characteristic of the chronic lymphocytic leukemia-associated phenotype found

41 Clonal expansion of B cell chronic lymphocytic leukemia (B-CLL) occurs within lymph

42 n detected in the peripheral blood of B-cell chronic lymphocytic leukemia (B-CLL) patients, but displ

43 Clinical progression of B cell chronic lymphocytic leukemia (B-CLL) reflects the clone'

44 atment of B cell neoplasms, including B cell chronic lymphocytic leukemia (B-CLL).

45 rutinib and for monocytes from patients with chronic lymphocytic leukemia being treated with ibrutini

46 Using transcriptome sequencing data from chronic lymphocytic leukemia, breast cancer and uveal me

47 ir activity against B cell lines and primary chronic lymphocytic leukemia cells in sera depleted of s

48 Moreover, PI(3,4)P2 depletion in primary chronic lymphocytic leukemia cells significantly impaire

49 egradation of BTK in patient-derived primary chronic lymphocytic leukemia cells.

50 demonstrated, with over two-thirds of B-cell chronic lymphocytic leukemia characterized by the deleti

51 kinase inhibitors (BTKi's) are effective in chronic lymphocytic leukemia (CLL) after previous progre

52 -genome sequencing of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and acute myeloid leu

53 ation in hematopoietic stem cells results in chronic lymphocytic leukemia (CLL) and CD8-positive peri

54 olent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infec

55 action of a long-known prognostic marker in chronic lymphocytic leukemia (CLL) and integrates its fu

56 are inversely correlated with DNA damage in chronic lymphocytic leukemia (CLL) and lymphoma patient-

57 of NHL revealed a striking contrast between chronic lymphocytic leukemia (CLL) and mantle cell lymph

58 ovided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymph

59 delalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymph

60 inhibitors, current treatment strategies for chronic lymphocytic leukemia (CLL) are not curative, and

61 essive role for tumor-expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease model.

62 hat have altered prognosis for patients with chronic lymphocytic leukemia (CLL) at diagnosis.

63 ull donor were more effectively activated by chronic lymphocytic leukemia (CLL) B-cell targets opsoni

64 point for progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) based on 3 randomized

65 A subset of chronic lymphocytic leukemia (CLL) BCRs interacts with A

66 brutinib represents a therapeutic advance in chronic lymphocytic leukemia (CLL) but as monotherapy pr

67 BT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problem

68 ous regression is a recognized phenomenon in chronic lymphocytic leukemia (CLL) but its biological ba

69 first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 19

70 Chronic lymphocytic leukemia (CLL) can be familial; howe

71 kemia) are present in approximately 4-13% of chronic lymphocytic leukemia (CLL) cases, where they are

72 dual disease (MRD) negativity, defined as <1 chronic lymphocytic leukemia (CLL) cell detectable per 1

73 rtant target for translational regulation in chronic lymphocytic leukemia (CLL) cells after B-cell re

74 nt5a enhanced proliferation and migration of chronic lymphocytic leukemia (CLL) cells and that these

75 Multiple studies show that chronic lymphocytic leukemia (CLL) cells are heavily dep

76 Chronic lymphocytic leukemia (CLL) cells cycle between l

77 Circulating chronic lymphocytic leukemia (CLL) cells display an abno

78 Chronic lymphocytic leukemia (CLL) cells express poor le

79 ate a microenvironmental glycolytic shift in chronic lymphocytic leukemia (CLL) cells mediated by Not

80 Chronic lymphocytic leukemia (CLL) cells multiply and be

81 The crucial dependence of chronic lymphocytic leukemia (CLL) cells on signals deri

82 The proliferation of chronic lymphocytic leukemia (CLL) cells requires commun

83 Wnt5a and ROR1 are expressed in circulating chronic lymphocytic leukemia (CLL) cells, and because in

84 stromal niche exerts a protective effect on chronic lymphocytic leukemia (CLL) cells, thereby also a

85 driver of the proliferation and survival of chronic lymphocytic leukemia (CLL) cells.

86 nt malignancies, as it is known from primary chronic lymphocytic leukemia (CLL) cells.

87 #8 is a distinctive subset of patients with chronic lymphocytic leukemia (CLL) defined by the expres

88 The prognosis of chronic lymphocytic leukemia (CLL) depends on different

89 Human and mouse chronic lymphocytic leukemia (CLL) develops from CD5(+)

90 A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or

91 morbidity and mortality among patients with chronic lymphocytic leukemia (CLL) due to immune dysfunc

92 mmune dysregulation is a cardinal feature of chronic lymphocytic leukemia (CLL) from its early stage

93 clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged b

94 The treatment of chronic lymphocytic leukemia (CLL) has been revolutioniz

95 The therapy of relapsed chronic lymphocytic leukemia (CLL) has changed dramatica

96 egative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well cha

97 Treatment of chronic lymphocytic leukemia (CLL) has shifted from chem

98 The management of chronic lymphocytic leukemia (CLL) has undergone dramati

99 ximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited.

100 c venetoclax in patients with poor prognosis chronic lymphocytic leukemia (CLL) highlights the potent

101 cells from 841 treatment-naive patients with chronic lymphocytic leukemia (CLL) identified 89 (11%) p

102 climbed up substantially since then, and the chronic lymphocytic leukemia (CLL) incidence has increas

103 Targeted therapies for chronic lymphocytic leukemia (CLL) include venetoclax, t

104 Current treatment strategies for chronic lymphocytic leukemia (CLL) involve a combination

105 Chronic lymphocytic leukemia (CLL) is a B cell malignanc

106 Chronic lymphocytic leukemia (CLL) is a common B-cell ma

107 Chronic lymphocytic leukemia (CLL) is a common B-cell ma

108 Chronic lymphocytic leukemia (CLL) is a common lymphoid

109 Chronic lymphocytic leukemia (CLL) is a disease in which

110 Chronic lymphocytic leukemia (CLL) is a heterogenous dis

111 Chronic lymphocytic leukemia (CLL) is a malignancy of ma

112 Chronic lymphocytic leukemia (CLL) is a malignant diseas

113 Chronic lymphocytic leukemia (CLL) is a variable disease

114 Chronic lymphocytic leukemia (CLL) is an incurable disea

115 Chronic lymphocytic leukemia (CLL) is characterized by i

116 Chronic lymphocytic leukemia (CLL) is characterized by t

117 Chronic lymphocytic leukemia (CLL) is characterized by t

118 The treatment landscape for chronic lymphocytic leukemia (CLL) is rapidly evolving.

119 The pathogenesis of chronic lymphocytic leukemia (CLL) is stringently associ

120 B-cell chronic lymphocytic leukemia (CLL) is the most common ad

121 Chronic lymphocytic leukemia (CLL) is the most common ad

122 Chronic lymphocytic leukemia (CLL) is the most common ad

123 Chronic lymphocytic leukemia (CLL) is the most common hu

124 B-cell chronic lymphocytic leukemia (CLL) is the most common hu

125 Chronic lymphocytic leukemia (CLL) is the most common hu

126 B-cell chronic lymphocytic leukemia (CLL) is the most common le

127 Chronic lymphocytic leukemia (CLL) is the most common le

128 the clinically relevant question of whether chronic lymphocytic leukemia (CLL) is transmitted throug

129 An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 g

130 (KI) therapy represents a paradigm shift in chronic lymphocytic leukemia (CLL) management, but data

131 p110deltaD910A/D910A) in the Emu-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell

132 Chronic lymphocytic leukemia (CLL) occurs in 2 major for

133 ents with hypogammaglobulinemia secondary to chronic lymphocytic leukemia (CLL) or multiple myeloma (

134 ion in a fraction of patients with high-risk chronic lymphocytic leukemia (CLL) or Richter's transfor

135 ed data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic

136 On real data from a chronic lymphocytic leukemia (CLL) patient, we show that

137 NOTCH1 is mutated in 10% of chronic lymphocytic leukemia (CLL) patients and is assoc

138 Chronic lymphocytic leukemia (CLL) patients assigned to

139 eripheral blood mononuclear cells (PBMCs) of chronic lymphocytic leukemia (CLL) patients clearly stat

140 age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at pa

141 Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical

142 Chronic lymphocytic leukemia (CLL) patients progressed e

143 proportion of long-term nonprogressors among chronic lymphocytic leukemia (CLL) patients suggests the

144 le responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with

145 In chronic lymphocytic leukemia (CLL) patients with mutated

146 nt advances in the therapeutic management of Chronic Lymphocytic Leukemia (CLL) patients, this common

147 herapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients.

148 levels are increased in cells and plasma of chronic lymphocytic leukemia (CLL) patients.

149 cell transplantation (SCT) availability for chronic lymphocytic leukemia (CLL) patients.

150 high-risk, untreated, and previously treated chronic lymphocytic leukemia (CLL) patients.

151 CR) is first-line treatment of medically fit chronic lymphocytic leukemia (CLL) patients; however, de

152 red ibrutinib resistance have suggested that chronic lymphocytic leukemia (CLL) progression on ibruti

153 B-cell receptor (BCR) signaling pathways in chronic lymphocytic leukemia (CLL) provides significant

154 which 78 previously untreated patients with chronic lymphocytic leukemia (CLL) received 8 cycles of

155 Chronic lymphocytic leukemia (CLL) remains an incurable

156 B-cell chronic lymphocytic leukemia (CLL) results from accumula

157 Chronic lymphocytic leukemia (CLL) risk stratification s

158 s, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival.

159 Chronic lymphocytic leukemia (CLL) therapy has changed d

160 meters are established prognostic factors in chronic lymphocytic leukemia (CLL) treated with chemoimm

161 Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutini

162 alk between CD4(+) T cells and proliferating chronic lymphocytic leukemia (CLL) tumor B cells occurs

163 ebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early

164 we studied the effect of USP7 inhibition in chronic lymphocytic leukemia (CLL) where the ataxia tela

165 Patients with chronic lymphocytic leukemia (CLL) who achieve blood or

166 fied T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously re

167 able to identify a subgroup of patients with chronic lymphocytic leukemia (CLL) who have an exception

168 ls from Emu-TCL1 transgenic mice resulted in chronic lymphocytic leukemia (CLL) with a biased reperto

169 Genetic instability is a feature of chronic lymphocytic leukemia (CLL) with adverse prognosi

170 Adoptive cell therapy of chronic lymphocytic leukemia (CLL) with chimeric antigen

171 Treatment of patients with chronic lymphocytic leukemia (CLL) with inhibitors of Br

172 , has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of

173 iated with resistance to targeted therapy of chronic lymphocytic leukemia (CLL) with the Bruton's tyr

174 aches, we consider the targeted treatment of chronic lymphocytic leukemia (CLL) with tyrosine kinase

175 Chronic lymphocytic leukemia (CLL) with unmutated (U-CLL

176 In chronic lymphocytic leukemia (CLL), acquired T-cell dysf

177 In chronic lymphocytic leukemia (CLL), AID is overexpressed

178 antitumor immune responses are hallmarks of chronic lymphocytic leukemia (CLL), and PD-1/PD-L1 inhib

179 CYP3A genotype and outcome in patients with chronic lymphocytic leukemia (CLL), breast, or lung canc

180 improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissi

181 mponent, are associated with poor outcome in chronic lymphocytic leukemia (CLL), but how these contri

182 netoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in

183 SF3B1 is recurrently mutated in chronic lymphocytic leukemia (CLL), but its role in the

184 ite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses a

185 oblastic leukemia but are less effective for chronic lymphocytic leukemia (CLL), focusing attention o

186 rkers were associated with increased risk of chronic lymphocytic leukemia (CLL), follicular lymphoma

187 We found that in chronic lymphocytic leukemia (CLL), HIF-1alpha is a nove

188 -cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), including the expans

189 In chronic lymphocytic leukemia (CLL), intra-tumoral DNA me

190 and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma

191 In chronic lymphocytic leukemia (CLL), neoplastic B cells e

192 s with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma (

193 h BTK inhibitors have transformed therapy in chronic lymphocytic leukemia (CLL), patients with high-r

194 R-15/16 is the most common genetic lesion in chronic lymphocytic leukemia (CLL), promoting overexpres

195 Within chronic lymphocytic leukemia (CLL), responses to 62% of

196 In chronic lymphocytic leukemia (CLL), signaling through se

197 In chronic lymphocytic leukemia (CLL), the immunoglobulin h

198 In chronic lymphocytic leukemia (CLL), the increment in PBL

199 In human chronic lymphocytic leukemia (CLL), tumor B cells lodge

200 to malignant B cells from 268 patients with chronic lymphocytic leukemia (CLL), we showed that tumor

201 the deregulation of the survival pathways in chronic lymphocytic leukemia (CLL), which is crucial to

202 uximab and bendamustine in older adults with chronic lymphocytic leukemia (CLL).

203 genome sequencing of bulk tumors, including chronic lymphocytic leukemia (CLL).

204 ti-CD20-opsonized B cells from patients with chronic lymphocytic leukemia (CLL).

205 ays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL).

206 erentiation and function and is disturbed in chronic lymphocytic leukemia (CLL).

207 b has dramatically changed the management of chronic lymphocytic leukemia (CLL).

208 the two largest disease categories: AML and chronic lymphocytic leukemia (CLL).

209 (BCR) are now prominent in the treatment of chronic lymphocytic leukemia (CLL).

210 revealed the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL).

211 promising clinical activity in patients with chronic lymphocytic leukemia (CLL).

212 ty, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL).

213 rituximab, in the majority of patients with chronic lymphocytic leukemia (CLL).

214 dard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL).

215 acy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).

216 tissue contributes to disease progression in chronic lymphocytic leukemia (CLL).

217 mumab) for treatment of B-cell lymphomas and chronic lymphocytic leukemia (CLL).

218 ipeline to analyze CSs and apply it to study chronic lymphocytic leukemia (CLL).

219 ibody with single-agent activity in relapsed chronic lymphocytic leukemia (CLL).

220 ts in this pathway fail to control growth of chronic lymphocytic leukemia (CLL).

221 gnaling is a central pathogenetic pathway in chronic lymphocytic leukemia (CLL).

222 ant therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).

223 is a major barrier to effective treatment of chronic lymphocytic leukemia (CLL).

224 athways plays a major role in progression of chronic lymphocytic leukemia (CLL).

225 with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL).

226 ented a significant treatment advancement in chronic lymphocytic leukemia (CLL).

227 of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL).

228 rstanding of the genomic alterations driving chronic lymphocytic leukemia (CLL).

229 proved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL).

230 of cases of MBL have the immunophenotype of chronic lymphocytic leukemia (CLL).

231 B-cell lymphocytosis (MBL) is a precursor of chronic lymphocytic leukemia (CLL).

232 and (autoantigen)- mediated BCR signaling in chronic lymphocytic leukemia (CLL).

233 ctivity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

234 cascade in the initiation and maintenance of chronic lymphocytic leukemia (CLL).

235 e genetic landscape and clonal complexity of chronic lymphocytic leukemia (CLL).

236 itor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL).

237 c strategy in B-cell malignancies, including chronic lymphocytic leukemia (CLL).

238 D49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL).

239 stic leukemia (T-ALL) and RPS15 mutations in chronic lymphocytic leukemia (CLL).

240 e, is an effective therapy for patients with chronic lymphocytic leukemia (CLL).

241 (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

242 R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL).

243 greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL).

244 be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL).

245 ve transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL).

246 ence for inherited genetic predisposition to chronic lymphocytic leukemia (CLL).

247 is common in many types of cancer, including chronic lymphocytic leukemia (CLL).

248 ption for patients with previously untreated chronic lymphocytic leukemia (CLL).

249 rotein, have been approved for patients with chronic lymphocytic leukemia (CLL).

250 d BTK active-site occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lym

251 classic chemoimmunotherapy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lym

252 improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lym

253 NF-kappaB is constitutively activated in chronic lymphocytic leukemia (CLL); however, the implica

254 t advance for the treatment of patients with chronic lymphocytic leukemia (CLL); however, their high

255 oclonal antibody (mAb), recently approved in chronic lymphocytic leukemia (CLL; B-cell CLL) and folli

256 = 28), low-grade B-cell lymphoma (n = 8), or chronic lymphocytic leukemia (CLL; n = 7).

257 n lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia [CLL]) outside of rare here

258 -positive cancers (non-Hodgkin's lymphoma or chronic lymphocytic leukemia [CLL]).

259 ording to the 2008 International Workshop on Chronic Lymphocytic Leukemia criteria.

260 fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course

261 Unlike cells of chronic lymphocytic leukemia, FL cells expressed relativ

262 Risks of chronic lymphocytic leukemia, follicular lymphoma, and m

263 d by 2008 Modified International Workshop on Chronic Lymphocytic Leukemia guidelines) from 31 centres

264 ic criteria of the International Workshop on Chronic Lymphocytic Leukemia, had received at least thre

265 uton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift

266 usceptibility Genes, Genetic Epidemiology of Chronic Lymphocytic Leukemia, Impact of Remote Familial

267 30 (60%), multiple myeloma in 17 (34%), and chronic lymphocytic leukemia in 3 (6%) patients.

268 ell lung cancer, acute myeloid leukemia, and chronic lymphocytic leukemia, in which the authors recon

269 In Emu-TCL1 mice with chronic lymphocytic leukemia, injection of the STING ago

270 We show that venetoclax resistance in chronic lymphocytic leukemia is associated with complex

271 ording to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eas

272 response [PR]) by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria was 71% (1

273 ompounds, including topoisomerase II, B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), and many

274 acute lymphoblastic leukemia (ALL; n = 47), chronic lymphocytic leukemia (n = 24), and non-Hodgkin l

275 ed or refractory kappa+ non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/CLL) or multiple myelo

276 by 4 cancer types (chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and

277 ment of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fi

278 tosus; lymphoproliferative disorders such as chronic lymphocytic leukemia or large granular lymphocyt

279 Subtype-specific analyses indicated that chronic lymphocytic leukemia or small lymphocytic lympho

280 ministration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lympho

281 We noted a marked association of sCD23 with chronic lymphocytic leukemia (ORSlope = 28, Ptrend = 7.2

282 Risk factors for basal cell carcinomas were chronic lymphocytic leukemia (P = 0.003), reduced-intens

283 carcinomas were increased age (P < 0.0001), chronic lymphocytic leukemia (P = 0.02), and chronic gra

284 onal heterogeneity within primary cells from chronic lymphocytic leukemia patients, but it can be ada

285 her, SIRT3 protein expression was reduced in chronic lymphocytic leukemia primary samples and maligna

286 and hsa-miR-150-5p in normal healthy serum, chronic lymphocytic leukemia Rai stage 1 (CLL-1), and st

287 Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and r

288 lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia (Richter transformation; n

289 eatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL).

290 IL33 mRNA expression was decreased in B cell chronic lymphocytic leukemia samples compared with healt

291 e positively associated with the risk of the chronic lymphocytic leukemia/small lymphocytic lymphoma

292 79% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

293 d among survivors of NHL, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma

294 Chronic lymphocytic leukemia/small lymphocytic lymphoma

295 In B-cell chronic lymphocytic leukemia, this is associated with po

296 cluding Crohn's disease, multiple sclerosis, chronic lymphocytic leukemia, veno-occlusive disease wit

297 patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated on a phase 1 d

298 ntle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled.

299 CL-2 antagonist, venetoclax, was approved in chronic lymphocytic leukemia, where it has proven to be

300 We describe a case involving a patient with chronic lymphocytic leukemia who developed invasive A. b